# Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Study · id `cardio:ct-nct05249920` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05249920](<https://clinicaltrials.gov/study/NCT05249920>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05249920

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1362 participants.

## Technical summary

Registry record NCT05249920. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2023-02-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1362 participants (enrolled count; ClinicalTrials.gov record NCT05249920, source copy `cardio:ctgov-nct05249920-2023-08-22`, retrieved 2026-10-26)
- Started: 2022-03-18 (actual) (ClinicalTrials.gov record NCT05249920, source copy `cardio:ctgov-nct05249920-2023-08-22`, retrieved 2026-10-26)
- Primary completion: 2023-02-17 (actual) (ClinicalTrials.gov record NCT05249920, source copy `cardio:ctgov-nct05249920-2023-08-22`, retrieved 2026-10-26)
- Completion: 2023-05-19 (actual) (ClinicalTrials.gov record NCT05249920, source copy `cardio:ctgov-nct05249920-2023-08-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05249920, source copy `cardio:ctgov-nct05249920-2023-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05249920-2023-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
- Condition: Acute Ischemic Stroke
- Condition: Mechanical Thrombectomy
- Condition: Edaravone Dexborneol
- Condition: Phase III
- Intervention (Drug): Edaravone Dexborneol Concentrated Solution for injection
- Intervention (Drug): Edaravone Dexborneol placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial (`cardio:pubmed-41500725`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9dd11e177256202a7a47b0e47ac0f23f05d861926dcf96c3f0ddf9a7b254fbb5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
